Vivace Therapeutics is developing small molecules Hippo-YAP pathway modulators as targeted therapies or immuno-oncology agents and bispecific antibodies to target cancer.
Vivace Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vivace-therapeutics-inc-” connections=”true” suffix=””]
Vivace is targeting Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers. Secondly, it is working on therapies based on antibodies called BINspecifics which are bi-specific irreversible non-covalent cell-type specific antibodies.These drugs hit cancer targets in specific and bind to them irreversibly.
In June 2017, Vivance raised $25 Mn Series B was led by new investor Cenova Capital and included Sequoia Capital China, Mission Bay Capital along with the exiting partners. Earlier in 2015, Canaan Partners and WuXi Healthcare Ventures co-led the companys $15 Mn Series A financing.